Business Context and Reporting Period
Company: IRADIMED CORP (IRMD)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal Year Ended December 31, 2025
Business Overview: IRADIMED develops, manufactures, and markets MRI-compatible medical devices, specifically non-magnetic IV infusion pump systems (MRidium 3870 and 3860+) and patient vital signs monitoring systems (3880). The company operates as a single segment and sells primarily to hospitals and acute care facilities in the U.S. (84% of revenue) and internationally (16% of revenue) via distributors.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $83.8 million | $73.2 million |
| Gross Profit | $64.3 million | $56.4 million |
| Gross Margin | 76.7% | 76.9% |
| Operating Income | $26.1 million | $22.0 million |
| Operating Margin | 31.2% | 30.0% |
| Net Income | $22.5 million | $19.2 million |
| Diluted EPS | $1.75 | $1.50 |
| Cash from Operations | $24.9 million | $25.6 million |
| Cash & Investments | $51.2 million | $52.2 million |
| Working Capital | $71.0 million | $66.7 million |
| Total Debt | $0 | $0 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 14.4% to $83.8 million, driven by a 16.4% increase in U.S. sales ($70.6 million) and a 4.8% increase in international sales ($13.3 million).
- Product Mix: Device revenue grew 15.5% to $60.0 million, led by higher unit sales of IV infusion pump systems. Disposables revenue increased 17.0% to $17.6 million.
- Operating Expenses: Total operating expenses rose to $38.2 million (45.5% of revenue) from $34.4 million (47.0% of revenue). General and Administrative expenses increased 12% due to regulatory costs and the new facility; Sales and Marketing expenses increased 12% due to commissions and travel.
- Facility Expansion: The company completed construction and moved into a new 62,000 sq. ft. corporate and manufacturing facility in Orlando, Florida, in Q3 2025. The project cost approximately $15.2 million and was funded entirely with cash.
- Product Launch: The MRidium 3870 MRI Compatible IV Infusion Pump System received FDA 510(k) clearance in May 2025, with first shipments occurring in December 2025.
Guidance, Outlook, and Risks
- Dividends: In February 2026, the Board increased the quarterly cash dividend to $0.20 per share (from $0.17).
- Outlook: Management expects continued growth driven by market education on the safety risks of non-MRI compatible pumps and expanded intra-hospital use of devices in critical care units. The company anticipates sufficient liquidity to fund operations for at least the next 12 months.
- Key Risks:
- Product Concentration: Significant dependence on a limited number of products (IV pumps and monitors).
- Supply Chain: Reliance on single-source suppliers for critical components, including non-magnetic ultrasonic motors (though the company began manufacturing these in-house in late 2024).
- Regulatory: Risks associated with FDA clearances, potential recalls, and changing international regulations (e.g., EU MDR).
- Key Person: Heavy reliance on founder and CEO Roger Susi for product development and strategic direction.
Investor Verification Checklist
- Unit Sales Growth: Verify the reported increase in cumulative unit sales (IV pumps: 13,098; Monitors: 3,397) against revenue growth to assess pricing trends.
- New Facility Impact: Confirm the depreciation schedule and overhead absorption for the new $15.2 million Orlando facility to ensure future margin stability.
- Supply Chain Resilience: Review the status of the technology transfer for the non-magnetic ultrasonic motor to confirm reduced reliance on the sole Japanese supplier.
- Deferred Revenue: Examine the $6.3 million in deferred revenue related to extended maintenance agreements to understand future revenue visibility.
- Regulatory Status: Monitor the FDA clearance status for any future product modifications and the impact of the EU Medical Device Regulation (MDR) on international sales.